Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

    NCT03942354 · start 2019-09-01

    Registered record
    Registry ID
    NCT03942354
    Conditions
    Multidrug Resistant Tuberculosis
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Directly observed therapy (DOT)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-01
    Completion
    2022-05-10
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhaseNot recorded
    Registry statusCompleted

  • Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

    NCT04062201 · start 2019-08-22

    Registered record
    Registry ID
    NCT04062201
    Conditions
    Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis
    Interventions
    Bedaquiline Oral Tablet; Linezolid Oral Tablet; Delamanid in Oral Dosage Form; Clofazimine Oral Product; Levofloxacin Oral Tablet; Isoniazid Oral Product; Ethambutol Oral Product; Pyrazinamide Oral Product; Linezolid Oral Tablet; Clofazimine Oral Product; Levofloxacin Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-22
    Completion
    2024-04-15
    Enrolment
    402

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis +1 more
    InterventionBedaquiline Oral Tablet; Linezolid Oral Tablet; Delamanid in Oral Dosage Form; Clofazimine Oral Product +7 more
    PhasePhase 3
    Registry statusCompleted

  • Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

    NCT03785106 · start 2019-08-15

    Registered record
    Registry ID
    NCT03785106
    Conditions
    HIV-infected Participants With Latent TB Infection in High TB Burden Country
    Interventions
    Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6); Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-08-15
    Completion
    2038-03
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-infected Participants With Latent TB Infection in High TB Burden Country
    InterventionIsoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6); Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
    PhasePhase 3
    Registry statusActive not recruiting

  • PRACTECAL-PKPD Sub Study

    NCT04081077 · start 2019-08-06

    Registered record
    Registry ID
    NCT04081077
    Conditions
    Multi-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculosis
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-08-06
    Completion
    2022-09-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculosis
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +1 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

    NCT03474029 · start 2019-08-01

    Registered record
    Registry ID
    NCT03474029
    Conditions
    Latent Tuberculosis
    Interventions
    Rifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks; Rifampin and Isoniazid daily for 12 weeks; Rifampin daily for 16 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2019-08-01
    Completion
    2029-12-31
    Enrolment
    3,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis
    InterventionRifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks; Rifampin and Isoniazid daily for 12 weeks; Rifampin daily for 16 weeks
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

    NCT03927313 · start 2019-06-12

    Registered record
    Registry ID
    NCT03927313
    Conditions
    Tuberculosis Meningitis; HIV-1-infection
    Interventions
    Linezolid; High dose rifampicin; Aspirin; Standard of Care anti-tuberculous therapy; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-06-12
    Completion
    2021-03-31
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Meningitis; HIV-1-infection
    InterventionLinezolid; High dose rifampicin; Aspirin; Standard of Care anti-tuberculous therapy +1 more
    PhasePhase 2
    Registry statusCompleted

  • The Role of Vitamin D, A, and Beta Carotene in Tuberculosis Patients With Vitamin D Receptor Gene Polymorphism

    NCT04593524 · start 2019-05-14

    Registered record
    Registry ID
    NCT04593524
    Conditions
    Tuberculosis
    Interventions
    vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling; nutritional Counseling
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-05-14
    Completion
    2019-09-22
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionvitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling; nutritional Counseling
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

    NCT03982277 · start 2019-04-30

    Registered record
    Registry ID
    NCT03982277
    Conditions
    Tuberculosis
    Interventions
    Rifampin 300 Mg Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-30
    Completion
    2021-07-23
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampin 300 Mg Oral Capsule
    PhasePhase 2
    Registry statusCompleted

  • Doravirine, Rifapentine and Isoniazid Interaction

    NCT03886701 · start 2019-04-22

    Registered record
    Registry ID
    NCT03886701
    Conditions
    Latent Tuberculosis; Human Immunodeficiency Virus; Rifamycins Causing Adverse Effects in Therapeutic Use; Drug Interaction Potentiation
    Interventions
    Doravirine (DOR); Rifapentine (RPT); Isoniazid (INH)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-22
    Completion
    2019-05-20
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; Human Immunodeficiency Virus; Rifamycins Causing Adverse Effects in Therapeutic Use; Drug Interaction Potentiation
    InterventionDoravirine (DOR); Rifapentine (RPT); Isoniazid (INH)
    PhasePhase 1
    Registry statusCompleted

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted

  • Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet

    NCT03800381 · start 2019-01-28

    Registered record
    Registry ID
    NCT03800381
    Conditions
    Tuberculosis; Human Immunodeficiency Virus; Coinfection
    Interventions
    Observational PK study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-28
    Completion
    2024-08-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus; Coinfection
    InterventionObservational PK study
    PhaseNot recorded
    Registry statusCompleted

  • Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults

    NCT05283967 · start 2019-01-01

    Registered record
    Registry ID
    NCT05283967
    Conditions
    Tuberculosis
    Interventions
    urine colorimetric assay
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-01
    Completion
    2023-12-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionurine colorimetric assay
    PhaseNot recorded
    Registry statusCompleted

  • Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)

    NCT03900858 · start 2018-12-01

    Registered record
    Registry ID
    NCT03900858
    Conditions
    Silicosis Tuberculosis
    Interventions
    Isoniazid；Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-12-01
    Completion
    2022-06-01
    Enrolment
    566

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSilicosis Tuberculosis
    InterventionIsoniazid；Rifapentine
    PhaseNot applicable
    Registry statusUnknown

  • Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

    NCT03338621 · start 2018-07-30

    Registered record
    Registry ID
    NCT03338621
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Drug-Resistant Tuberculosis
    Interventions
    Pretomanid; Bedaquiline; Moxifloxacin; Pyrazinamide; HRZE; HR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-07-30
    Completion
    2022-06-10
    Enrolment
    455

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis +1 more
    InterventionPretomanid; Bedaquiline; Moxifloxacin; Pyrazinamide +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

    NCT03625739 · start 2018-07-01

    Registered record
    Registry ID
    NCT03625739
    Conditions
    Tuberculosis
    Interventions
    anti-tuberculosis drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-07-01
    Completion
    2026-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionanti-tuberculosis drug
    PhaseNot recorded
    Registry statusRecruiting